December 19, 2023 06:36 AM ESTUpdated 07:19 AM

Ionis divests commercial EU rights for rare disease candidate to Otsuka for $65M upfront

Ayisha Sharma

News Reporter

Ionis Pharmaceuticals has inked a deal with Otsuka, giving the Japanese pharma European commercial rights to its Phase III prophylactic drug candidate for hereditary angioedema …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ionis divests commercial EU rights for rare disease candidate to Otsuka for $65M upfront

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Tang Capital’s Concentra bids for Singular Genomics days after Deerfield offer

Breaking down silos with a new quantitative approach to drug development

Io­n­is di­vests com­mer­cial EU rights for rare dis­ease can­di­date to Ot­su­ka for $65M up­front

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Tang Cap­i­tal’s Con­cen­tra bids for Sin­gu­lar Ge­nomics days af­ter Deer­field of­fer

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Ionis divests commercial EU rights for rare disease candidate to Otsuka for $65M upfront

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Tang Capital’s Concentra bids for Singular Genomics days after Deerfield offer

Breaking down silos with a new quantitative approach to drug development